Semiannual Securities Report — FY2026 H1
What SANTEN PHARMACEUTICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-09View the original on EDINET
How much it says
60Detailed
What moved here
31named for the first time
Its own wording
60terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, revenue was ¥143.3 billion, operating profit was ¥19.4 billion, and interim profit was ¥15.5 billion. The document also states that the liquidation of Plano Pte. Ltd. was completed, that all shares of AVS were transferred to SpyGlass Pharma, Inc. on 1 October 2026 and AVS was removed from the consolidated subsidiaries, and that resolutions were made on the repurchase of treasury shares and the interim dividend.
Komori's summary of this document, not the document's own words.60Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
70
Detailed
38
Thin
38
Thin
0
Almost nothing
100
Very detailed
53
Typical
100
Very detailed
62
Detailed
69
Detailed
35
Thin
73
Detailed
R&D spend123億円Money spent making new things.
Cash left over111億円Cash from the business, less what went into equipment.
Spent on equipment49億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.